Dr Kinan Mokbel

Kinan Mokbel is a Senior Academic Lecturer in the Faculty of Health and Life Sciences at the University of Exeter and an Honorary Visiting Professor at Brunel University London. He combines extensive experience in clinical research and higher education, working as a Research Fellow on the ERASE-LC study and holding an Honorary Senior Research Fellowship at the London Breast Institute, The Princess Grace Hospital, London.

Kinan lectures in Clinical Pharmacy, Advanced Clinical Practice, Clinical Research and Pharmacology. With over twenty years of experience as a pharmacist across healthcare practice and clinical research, Kinan is a dedicated academic who has taught on undergraduate, postgraduate and professional development programmes for practising pharmacists. Kinan currently provides academic leadership as Module Lead for core modules within both the MSc Clinical Pharmacy and MSc Advanced Clinical Practice programmes:

• Long-Term Condition Care (Respiratory, Endocrine, and Renal)
• Long-Term Condition Care (Cardiovascular)

Kinan is also the Pharmacology Strand Lead within the Nursing Academy, overseeing pharmacology teaching across all four years of the MSci Nursing programme and supporting students throughout their training. This integrated four-year Master’s degree leads to an MSci Nursing qualification and registration with the Nursing and Midwifery Council (NMC).

Alongside his teaching, Kinan is a Research Fellow on the ERASE-LC study, where he is the primary patient contact and is responsible for coordinating the safe delivery of clinical assessments and treatments. He previously held a Postdoctoral Research Fellowship in the Department of Health and Community Sciences at the University of Exeter, contributing to the Spotting Cancer among Comorbidities (SPOCC) programme - an NIHR-funded project with University College London. His research focused on help-seeking behaviour and the early identification of cancer in patients with existing comorbidities.

Kinan also holds an Honorary Visiting Professorship at Brunel University London and an Honorary Senior Research Fellowship at the London Breast Institute, The Princess Grace Hospital, London. In these roles, he works with a multidisciplinary research team exploring the genetic influences on treatment response and the development of novel cancer therapeutics.

"Kinan welcomes enquiries from motivated undergraduate, MSc and PhD students interested in research aligned with his expertise and interests. He is also open to collaboration with visiting students and scholars, and encourages anyone interested in potential opportunities to contact him by email".

Qualifications

• Master of Pharmacy
• Post-graduate Certificate in Pharmacy Education Development
• Master of Science in Clinical Pharmacy
• Master of Science in Genomic Medicine
• PhD - Pharmacogenomics of Medically Important Adverse Drug Effects
• Learning & Teaching in Higher Education (LTHE)
• ASPIRE Higher Education Academy Associate Fellowship
• Fellow of the Higher Education Academy (FHEA)

Research projects

• ERASE – long COVID (Clinical feasibility study of the efficacy of Remdesivir for long COVID)
• LOCOMUS study (Long COVID related inflammatory processes. What is its association on bone, joints, and musculoskeletal microvascular haemodynamics?)
• SPOCC: SPOtting Cancer among Comorbidities.
• Pharmacogenomics of Medically Important Adverse Drug Effects. Learn about genomic medicine and pharmacy practice.
• Assessing the prevalence of genotypes conferring risk of severe adverse drug reactions in participants of UK Biobank. Learn about Genomics for Pharmacy and its significance in pharmacy practice.

Research group links

• Exeter Collaboration for Academic Primary Care (APEx)
• ERASE – long COVID (Clinical feasibility study of the efficacy of Remdesivir for long COVID)

Research interests

• Genomic profiling for chemotherapy recommendations in breast and colorectal cancers.
• Prognostication tools in the context of adjuvant treatment of early breast cancer.
• Genetic testing in clinical practice.
• Pharmacogenomics of adverse drug effects.
• Spotting cancer among comorbidities and supporting clinical decision-making in patients with symptoms of cancer and pre-existing conditions
• Long COVID
• Safety of medicines in general practice and the role of community pharmacists in addressing adverse drug effects.
• Chemoprevention of breast and prostate cancers with vitamins and micronutrients.
• How Islamic cultural values shape health narratives in Muslim communities.

Conferences and invited presentations

The Clinical Pharmacy Congress 9-10 May 2025, London, England. Expanding Pharmacy Services with Point-of-Care Testing for Strep A as a Model for Future Care - Driving Down Antibiotic Prescriptions from the Heart of the Community through Point-of-Care Testing. Author URL.

Annual Scientific Meeting of the Pharmacogenomics Global Research Network (PGRN) September 23-25, 2024 at the Ohio State University in Columbus, Ohio, USA. Atlas of Pharmacogenomic Variants Underpinning Adverse Drug Effects: Unveiling Critical Insights for Advancing Precision Medicine. Author URL.

The Clinical Pharmacy Congress 10-11 May 2024, London, England. The Impact of the COVID-19 Pandemic on Medication Prescribing Patterns in General Practice: A Retrospective Time-trend Analysis. Abstract.

The Clinical Pharmacy Congress North 3-4 November 2023, Manchester, England. A Nationwide Comparative Safety Study of Medicines Within the Therapeutic Class: A Novel Data Integration Approach Based on the Yellow Card Reporting Scheme and the English General Practice Prescription Data. Abstract.

The 7th International Congress of the European Society for Pharmacogenomics and Personalised Therapy (ESPT), October 25-27th, 2023, Copenhagen, Denmark. Pharmacogenomic Variants of Medically Important Adverse Effects Related to High-Risk Medicines in General Practice Can Not Be Replicated in UK Biobank. Abstract.

The 16th Annual Meeting of Korean Society of Medical Oncology & 2023 International Conference & 11th International FACO Conference, September 7th to 8th 2023, Seoul, Korea. Pharmacogenetics of Endocrine Therapy Associated Toxicities in Breast Cancer. Author URL.

The European Society of Human Genetics Conference, June 10–13th, 2023, Glasgow, Scotland, UK. The Majority of Pharmacogenomic Variants Associated with Adverse Drug Events When Taking Endocrine Therapies for Breast Cancer Can Not Be Replicated in UK Biobank Participants. Author URL.

The Association for Cancer Surgery Annual Scientific Conference and NCRI Cancer Conference 5th–8th November 2017 Liverpool, UK. A comparison of the performance of EndoPredict Clinical and NHS PREDICT in 120 patients treated for ER+ breast cancer. Author URL.

Manuscript(s) under consideration

• Endocrine Therapy and Medically Important Adverse Drug Effects: A Pharmacogenomic Investigation in Breast Cancer Patients in UK Biobank.
• Preoperative Diagnostic Gaps and Evolving Standards in Early Breast Cancer Management: Insights from the CONSCIENCE Study.
• Interventions for improving the early detection of cancer in primary care patients with anxiety and/or depression: a systematic review and narrative synthesis.
• Contactin-1 in human colon cancer identifies patients with poor clinical outcome in the context of lymph node positivity and Dukes staging.
• PPP2R4 and its regulatory units in colon cancer.
• Assessment of Bone Mineral Density, Total Body Composition and Joint Integrity in Long COVID: A 12-Month Longitudinal Feasibility Study.